Aethlon Medical Inc.
AEMD
NSC
Sector: Technology
Industry: Scientific & Technical Instruments
1.27
USD
-0.07
(-5.22%)
Optionable: Yes Market Cap: 29 M 90-day average vol: 4,539,443
Previous close: 1.34 Open: 1.28 Bid: 1.27 Ask: 1.27
52 week range
0.88 5.99
Last updated: Wednesday 17th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 179.30 |
Price per Book TTM ($) | 2.04 |
PE Ratio (TTM) | -1.80 |
Book Value per Share ($) | 1.03 |
5 Year PE Range | -3.1 , -2.2 |
Returns
7 Day Return | -3.05% | |
1 Month Return | 19.81% | |
3 Month Return | 18.69% | |
1 Year Return | -64.02% | |
3 Year Return | -67.44% | |
5 Year Return | -94.77% | |
YTD Return | -31.72% |
Risk
Custom Beta One Year | 1.36 |
Custom Beta Three Years | 0.40 |
Beneish M Score | -3.17 |
Altman Z Score | -10.86 |
Financial Health
Technicals
RSI (14 Day) | 48.95 |
14 Day SMA ($) | 1.43 |
14 Day EMA ($) | 1.36 |
Money Flow Index | 63.74 |
Average True Range | 0.23 |
50 Day SMA ($) | 1.17 |
200 Day SMA ($) | 1.58 |
ADX | 32.30 |
MACD | 0.06 |
Growth
Free Cash Flow QoQ Growth | 44.69% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 23.08% |
Revenue QoQ Growth | -87.03% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -69.24 |
Profit Margin TTM (%) | -3542.5 |
Return on Equity TTM (%) | -78.42 |
Return on Capital TTM (%) | -76.21 |
Interest Coverage Ratio | -83,366.10 |
Gross Margin TTM (%) |
Chart
News
AEMD: Positive Takeaways from Plan to Expand Clinical Efforts
Yahoo Finance 2/15/2022
Aethlon Medical's (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha 2/14/2022
Aethlon Medical GAAP EPS of -$0.16 misses by $0.02, revenue of $0.02M misses by $0.19M
Seeking Alpha 2/14/2022
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Yahoo Finance 2/14/2022
Aethlon Medical Q3 2022 Earnings Preview
Seeking Alpha 2/11/2022
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022
Yahoo Finance 1/31/2022
Here's Why We're Not Too Worried About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
Yahoo Finance 11/30/2021
AEMD: Strong balance sheet, expanded management team & new CRO relationship expected to facilitate clinical efforts
Yahoo Finance 11/12/2021
Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha 11/9/2021
Aethlon Medical EPS beats by $0.02, misses on revenue
Seeking Alpha 11/9/2021
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
Yahoo Finance 11/9/2021
Aethlon Medical FQ2 2022 Earnings Preview
Seeking Alpha 11/8/2021
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021
Yahoo Finance 11/2/2021
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
Yahoo Finance 10/12/2021
Aethlon Medical announces contracting with PPD to advance Hemopurifier clinical programs
Seeking Alpha 9/30/2021
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
Yahoo Finance 9/30/2021
Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Yahoo Finance 9/7/2021
10 Penny Stocks Redditors are Buying in August
Yahoo Finance 8/12/2021
AEMD: Strong Cash Position to Advance the Hemopurifier; Clinical Trials Move Forward
Yahoo Finance 8/11/2021
Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript
Seeking Alpha 8/9/2021
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
Yahoo Finance 8/9/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 35.341
Financials
AEMD Income Statement
Annual
| Mar-13 | Mar-14 | Mar-15 | Mar-16 | Mar-17 | Mar-18 | Mar-19 | Mar-20 | Mar-21 | Mar-22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 M | 2 M | 762417 | 886572 | 392073 | 149625 | 229625 | 650187 | 659104 | 294165 |
| Cost of sales | -10484 | -21087 | -37352 | -38524 | -32413 | -35658 | -30695 | -26366 | -39939 | -123685 |
| Gross operating profit | 1 M | 2 M | 762417 | 886572 | 392073 | 149625 | 229625 | 650187 | 659104 | 294165 |
| Selling Gen & administrative expense | 5 M | 5 M | 5 M | 5 M | 6 M | 5 M | 6 M | 7 M | 9 M | 11 M |
| Research & development expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | -4 M | -3 M | -4 M | -4 M | -6 M | -5 M | -6 M | -6 M | -8 M | -10 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -184372 | -9 M | -3 M | 0 | -904039 | -507124 | 0 | -395821 | 0 | 0 |
| Pre-tax Income (EBT) | -5 M | -13 M | -7 M | -5 M | -7 M | -6 M | -6 M | -6 M | -8 M | -10 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -5 M | -13 M | -7 M | -5 M | -7 M | -6 M | -6 M | -6 M | -8 M | -10 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -5 M | -13 M | -7 M | -5 M | -7 M | -6 M | -6 M | -6 M | -8 M | -10 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -5 M | -13 M | -7 M | -5 M | -7 M | -6 M | -6 M | -6 M | -8 M | -10 M |
| Depreciation | 10484 | 21087 | 37352 | 38524 | 32413 | 35658 | 30695 | 26366 | 39939 | 123685 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -4 M | -12 M | -6 M | -4 M | -7 M | -5 M | -6 M | -6 M | -8 M | -10 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -22.5 | -51.6 | -18.3 | -9.9 | -14.1 | -6.9 | -5.13 | -1.87 | -0.65 | -0.71 |
| Diluted EPS total | -22.5 | -51.6 | -18.3 | -9.9 | -14.1 | -6.9 | -5.13 | -1.87 | -0.65 | -0.71 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!